![Anti-Cytochrome P450 3A5 [F18P3B6] - Image 2](https://cdn-ilckdcl.nitrocdn.com/MBaePtwnBApFeVkjJnkSzqjAKXyRSkYH/assets/images/optimized/rev-deed832/cancertools.org/wp-content/uploads/3ffb57db-32e6-4e5e-875b-1b7bbbf9bf78.jpg)
Cat. #151863
Anti-Cytochrome P450 3A5 [F18P3B6]
Cat. #: 151863
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CYP3A5- Cytochrome P450 3A5 (EC 1.14.14.1) (niphedipine oxidase), (CYPIIIA5) (P450-PCN3) (HLp2).
Class: Monoclonal
Application: IHC ; WB ; ELISA ; IHC ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ayham Alnabulsi
Institute: Vertebrate Antibodies Limited
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cytochrome P450 3A5 [F18P3B6]
- Research fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
- Clone: F18P3B6
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: IHC ; WB ; ELISA ; IHC ; WB
- Description: This monoclonal antibody (MAb), when used in conjunction with the MAb specific to CYP3A7 clone F19 P2 H2, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7.
- Immunogen: Ovalbumin-conjugated synthetic peptide DSRDGTLSGE (C-terminal sequence)
- Isotype: IgG1 kappa
- Myeloma used: P3X63Ag8.653
- Recommended controls: IHC: formalin-fixed, paraffin-embedded squamous oesophagus cancer sections western blot: recombinant P450 (shown below @ 0.5 pmol per lane).
Target Details
- Target: CYP3A5- Cytochrome P450 3A5 (EC 1.14.14.1) (niphedipine oxidase), (CYPIIIA5) (P450-PCN3) (HLp2).
- Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded squamous oesophagus cancer sections western blot: recombinant P450 (shown below @ 0.5 pmol per lane).
- Target background: This monoclonal antibody (MAb), when used in conjunction with the MAb specific to CYP3A7 clone F19 P2 H2, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7.
Applications
- Application: IHC ; WB ; ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Zia et al. 2015. Int J Exp Pathol. 96(2):81-6. PMID: 25670065.
- CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
- Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162.
- Profiling the expression of cytochrome P450 in breast cancer.
- Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
- Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
- Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
- Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.
- Kosik et al. 1992. Science. 256(5058):780-3. PMID: 1589757.
- Alzheimer's disease: a cell biological perspective.
